Cover Image
市場調查報告書

痙攣:開發中產品分析

Spasticity - Pipeline Review, H1 2015

出版商 Global Markets Direct 商品編碼 192831
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
痙攣:開發中產品分析 Spasticity - Pipeline Review, H1 2015
出版日期: 2015年05月29日 內容資訊: 英文 85 Pages
簡介

所謂痙攣,是具有肌肉控制障礙、肌肉緊張或僵硬、以及無法控制這些肌肉為特徵的疾病。其症狀有肌肉緊張、疼痛、姿勢異常及骨骼、關節變形。痙攣的治療包含了肌肉鬆弛劑等的投藥療法及物理療法。

本報告提供痙攣的治療藥開發情形調查分析,提供開發中產品的概要,臨床實驗各階段的產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

痙攣概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的的開發企業

  • Novartis AG
  • Merz Pharma GmbH & Co. KgaA.
  • Addex Therapeutics.
  • GW Pharmaceuticals plc
  • Sanochemia Pharmazeutika AG.
  • Raptor Pharmaceuticals Corp.
  • Osmotica Pharmaceutical Corp.
  • Intec Pharma ltd.
  • Concert Pharmaceuticals, Inc.
  • BiRDS Pharma GmbH.
  • Echo Pharmaceuticals B.V.
  • Canbex Therapeutics Ltd.
  • SciFluor Life Sciences, LLC.
  • Escape Therapeutics, Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • nabikishimorusu
  • arbaclofen ER
  • onabotulinumtoxinA
  • selurampanel
  • doronabinoru
  • CTP-354
  • bakurofenGR
  • VSN-16R
  • BDD-10103
  • NGX-426
  • tezampanel
  • ADX-71441
  • onabotulinumtoxinA
  • ruperizon
  • 痙攣小分子

開發中產品的最新趨勢

暫停的計劃

中止的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6722IDB

Summary

Global Markets Direct's, 'Spasticity - Pipeline Review, H1 2015', provides an overview of the Spasticity's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Spasticity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spasticity and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Spasticity
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Spasticity and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Spasticity pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Spasticity
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Spasticity pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Spasticity Overview
  • Therapeutics Development
    • Pipeline Products for Spasticity - Overview
    • Pipeline Products for Spasticity - Comparative Analysis
  • Spasticity - Therapeutics under Development by Companies
  • Spasticity - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Spasticity - Products under Development by Companies
  • Spasticity - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Canbex Therapeutics Ltd.
    • Concert Pharmaceuticals, Inc.
    • Daewoong Pharmaceutical Co., Ltd.
    • Echo Pharmaceuticals B.V.
    • GW Pharmaceuticals plc
    • Ipsen S.A.
    • Merz Pharma GmbH & Co. KgaA
    • OBI Pharma, Inc.
    • Osmotica Pharmaceutical Corp.
    • Sanochemia Pharmazeutika AG
    • SciFluor Life Sciences, LLC
    • Sun Pharma Advanced Research Company Ltd.
  • Spasticity - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abobotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • arbaclofen ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • baclofen ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTP-354 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dronabinol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • incobotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nabiximols - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NB-2221 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OBI-858 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • onabotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Spasticity - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tolperisone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VSN-16R - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Spasticity - Recent Pipeline Updates
  • Spasticity - Dormant Projects
  • Spasticity - Discontinued Products
  • Spasticity - Product Development Milestones
    • Featured News & Press Releases
      • Jan 26, 2015: Ipsen announces topline results of two double-blind phase III studies of Dysport in lower limb spasticity in children and in adults
      • Nov 28, 2014: Ipsen Announces FDA Acceptance of Filing for Dysport in the Treatment of Upper Limb Spasticity in Adult Patients
      • Nov 14, 2014: Ipsen Biopharmaceuticals Presents Dysport (abobotulinumtoxinA) Data at American Academy of Physical Medicine and Rehabilitation Annual Assembly
      • Oct 13, 2014: Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity
      • Jul 16, 2014: Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity
      • Jul 11, 2014: Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe
      • Apr 12, 2014: Ipsen announces a first set of results on positive phase III clinical study of Dysport in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul
      • Dec 17, 2013: Ipsen announces positive initial results from the international double-blind clinical phase III study of Dysport in the treatment of Adults suffering from Upper Limb Spasticity
      • Oct 02, 2013: GW Pharmaceuticals Announces New Sativex Data at ECTRIMS
      • Aug 14, 2013: GW Pharmaceuticals Opens an Investigational New Drug Application in the United States for a Sativex Phase 3 Clinical Program as a Treatment for Spasticity Due to Multiple Sclerosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Spasticity, H1 2015
  • Number of Products under Development for Spasticity - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Late Stage Development, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Spasticity - Pipeline by Addex Therapeutics Ltd, H1 2015
  • Spasticity - Pipeline by Canbex Therapeutics Ltd., H1 2015
  • Spasticity - Pipeline by Concert Pharmaceuticals, Inc., H1 2015
  • Spasticity - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015
  • Spasticity - Pipeline by Echo Pharmaceuticals B.V., H1 2015
  • Spasticity - Pipeline by GW Pharmaceuticals plc, H1 2015
  • Spasticity - Pipeline by Ipsen S.A., H1 2015
  • Spasticity - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015
  • Spasticity - Pipeline by OBI Pharma, Inc., H1 2015
  • Spasticity - Pipeline by Osmotica Pharmaceutical Corp., H1 2015
  • Spasticity - Pipeline by Sanochemia Pharmazeutika AG, H1 2015
  • Spasticity - Pipeline by SciFluor Life Sciences, LLC, H1 2015
  • Spasticity - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Spasticity Therapeutics - Recent Pipeline Updates, H1 2015
  • Spasticity - Dormant Projects, H1 2015
  • Spasticity - Dormant Projects (Contd..1), H1 2015
  • Spasticity - Discontinued Products, H1 2015

List of Figures

  • Number of Products under Development for Spasticity, H1 2015
  • Number of Products under Development for Spasticity - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Late Stage Development, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Products, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top